Associate Director, Health Science Executive of Boehringer Ingelheim; Co-Chair, AAPI Industry Physician Committee and Scientific Advisor to AAPI; Fellow of American College of Healthcare Executives; Has 15 Years' Experience in Healthcare Marketing, Sales and Business Development
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT), http://www.pvct.com, a development-stage oncology and dermatology biopharmaceutical company, announced that it has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, to its Strategic Advisory Board.
"Adding Dr. Chalil to our Strategic Advisory Board will strengthen our collective expertise in healthcare marketing, sales and business development. His depth and breadth of experience in these fields will enable Provectus to take greater advantage of the opportunities that lie ahead."
Dr. Chalil is Associate Director, Health Science Executives of Boehringer Ingelheim, the world's largest privately held pharmaceutical company. Headquartered in Ingelheim, Germany, the company operates globally in more than 50 countries. In 2012, Boehringer Ingelheim achieved net sales of 19.1 billion (USD); R&D expenditure in the business area of prescription medicines reached a quarter of its net sales.
In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Co-Chair for the Industry Physician Committee of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past three years. AAPI is the second largest physician organization in the US second only to AMA, and the largest ethnic medical organization in the country.
A veteran of the United States Navy Medical Corps, Dr. Chalil is also board certified in healthcare management, and has been awarded Fellowship by the American College of Healthcare Executives, an international professional society of more than 40,000 healthcare executives who lead hospitals, healthcare systems and other healthcare organizations.
Dr. Chalil is an expert in US Healthcare policy and a strong advocate for patient centered care, and has also served as an advisor to various national political campaigns on healthcare issues.
As the former CEO of Clinical Consultants International, he represented prominent healthcare companies, including GE Healthcare, Genpact, HIRCO Group, Godrej Ltd, KLE University, Somaiya Group, Pushpanjali Crosslay Hospital, Excel Life Sciences and various international pharmaceutical firms over the past decade.
Dr. Chalil completed his higher studies in University of Medicine and Dentistry of New Jersey, Davenport University, JJM Medical College and Baylor College of Medicine. He has been a Visiting Professor at various Universities and serves on various company Boards.
Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said, "Adding Dr. Chalil to our Strategic Advisory Board will strengthen our collective expertise in healthcare marketing, sales and business development. His depth and breadth of experience in these fields will enable Provectus to take greater advantage of the opportunities that lie ahead."
Dr. Chalil said, "I am honored to join the Provectus Strategic Advisory Board at this critical juncture of the company's development as it brings PV-10 and other treatments through the developmental regulatory approval processes."
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50819566&lang=en
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, 212-564-4700
DM, SVP – Investor Relations
Bill Gordon, 212-724-6312